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ABSTRACT - We conducted an open, add-on study with topiramate (TPM) as adjunctive therapy in Lennox-
Gastaut syndrome (LGS), to assess the long-term efficacy and safety and to evaluate quality of life (QL)
measurements in the chronic use of TPM. We studied 19 patients (11 male; age ranging from 4 to 14 years) with
uncontrolled seizures receiving 2-3 anti-epileptic drugs. Patients were followed up to 36 months of treatment. A
questionnaire was used to query parents about QL. Seven patients completed the study at 36 months and seizure
frequency was reduced  > 75% in 4, and < 50% in 3 patients. Two children became seizure free for more than 24
months. Most side effects were CNS related, with the most frequent being somnolence and anorexia. These were
generally transient. One patient dropped-out due to powder in the urine. None of the patients required
hospitalization. At 36 months, patients’ alertness (2/7), interaction with environment (5/7), ability to perform
daily activities (5/7), and verbal performance (6/7) improved on TPM. We conclude that TPM may be useful as
adjunctive therapy in the treatment of LGS. The efficacy of TPM was maintained in long-term treatment in more
than 40% of patients, long term safety was confirmed and QL improved on TPM.
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Estudo piloto com topiramato em crianças com síndrome de Lennox-Gastaut
RESUMO - Realizamos estudo aberto, de adição do topiramato (TPM) como medicação adjuvante no tratamento
da síndrome de Lennox-Gastaut (SLG), com a finalidade de verificar a eficácia e a segurança de avaliar a qualidade
de vida (QV) no uso crônico do TPM. Estudamos 19 pacientes (11 do sexo masculino; idade entre 4 e 14 anos)
com epilepsia de difícil controle e em uso de 2 a 3 drogas anti-epilépticas. Os pacientes foram seguidos por 36
meses. Um questionário foi aplicado aos pais para se avaliar QV. Sete crianças completaram o estudo. A frequência
de crises foi reduzida em mais de 75% em 4 e em menos de 50% em 3 delas. Dois pacientes ficaram sem crises.
A maioria dos efeitos colaterais relacionou-se ao sistema nervoso central, sendo sonolência e anorexia os mais
frequentes e transitórios. Um paciente foi excluído do estudo por apresentar pó na urina. Nenhuma criança
necessitou de hospitalização. Aos 36 meses, os pacientes encontravam-se mais alertas (2/7), e houve melhora na
interação com o meio ambiente (5/7), na habilidade em realizar tarefas diárias (5/7) e na performance verbal (6/
7). Concluímos que o TPM pode ser útil como terapia adjuvante na SLG. A eficácia manteve-se no tratamento a
longo prazo em mais de 40% dos pacientes, a segurança foi confirmada e a QV melhorou com o uso do TPM.
Palavras-chave: síndrome de Lennox-Gastaut, topiramato, tratamento de epilepsia.
Topiramate (TPM), a novel antiepileptic drug (AED), has multiple mechanisms of action1, 2
suggesting that it may be useful in a broad spectrum of seizure types, including those usually present
in Lennox-Gastaut syndrome (LGS).
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To date, there is no satisfactory and efficacious treatment available for LGS. Epilepsy surgery
may lead to improvement in some patients but it usually does not eliminate all seizures3. Felbamate
has been approved for the treatment of LGS in the United States, although the incidence of rare but
serious effects of aplastic anemia and liver failure has limited its usefulness4, 5. Finding the best
treatment for LGS is still a challenge. The current drug treatment of this syndrome usually requires
polypharmacy. Therefore, AED interaction is always a concern in the management of such patients.
Choosing drugs with the least possible interaction potential is a reasonable goal. Previous studies with
TPM6-8 have shown that there were no major interactions during coadministration with standard AEDs.
TPM demonstrates most of the pharmacokinetic properties considered ideal for an AED9,
such as fast and complete absorption, linear pharmacokinetics, predominantly renal elimination as
mainly an intact drug, low level of plasma protein binding, minimal interaction with other AEDs
and long half-life. On the basis of those findings and the multiple mechanisms of action of TPM we
considered that this could be a new good option in the treatment of LGS.
In order to investigate this hypothesis a protocol was designed which aimed to evaluate the
efficacy and safety of TPM as adjunctive therapy in LGS. An extension phase was designed in order
to assess the long-term efficacy and safety of TPM. We also intended to evaluate quality of life (QL)
measurements in the chronic use of TPM.
METHOD
Subject Population
We studied 19 patients with LGS: 11 male and 8 female with age ranging from 4 to 14 years. LGS was
defined by multiple seizure types, including atypical absence and drop attacks, slow spike wave EEG patterns
with abnormal background activity, mental retardation and resistance to standard AEDs10, 11. Patients had
uncontrolled seizures and were receiving 2 to 3 AEDs. Five of our patients were not presenting drop-attacks at
the time of the enrollment but they have had such seizures in other period of their lives and the EEG was still
consistent with LGS. In this syndrome, drop-attacks can usually be seen at some time in the course of the
affection and may modify with the evolution11, 12.
Demographic data, seizure types, etiology and medications at baseline are presented in Table 1. All
patients had had previous computed tomographic or magnetic resonance evaluations. Children were recruited
from 2 different centers.
Exclusion criteria carefully eliminated subjects with progressive neurological disorders, correctable cause
of their seizures, significant history of other diseases, anoxic episodes within the past year, inadequate parent/
guardian supervision, and history of a psychiatric disorder. Subjects on ketogenic diets or who have received
ACTH or Acetazolamide within the last six months were also excluded.
The institutional review board approved the protocol and informed consent was obtained prior to performing
trial related procedures from parents or guardians.
Study Design
There were four phases of this study: baseline period, titration (visits 1 to 4), stabilization (visits 5 and 6)
and extension (from visit 7 on). The baseline phase lasted one month and was designed to perform clinical and
laboratory evaluation covering medical history, seizure counting based on diary, laboratory tests (including
hematology, biochemistry, liver function, kidney function and pregnancy testing for childbearing potential girls),
electrocardiogram, electroencephalogram and dosage of AEDs other than TPM.
Titration phase: this phase consisted of TPM dose escalation from 1 mg/kg/day to 9 mg/kg/day (maximum
800 mg/day) over 4 weeks. The trial medication was gradually increased and adjusted every week during a 4-
week period according to the clinical response. A fixed titration schedule was used: 1, 3, 6, 9 mg/kg/day in the
first, second, third and fourth week subsequently. The schedule could be interrupted if maximum tolerated dose
would be achieved. Patients were assessed every week.
The stabilization phase lasted 4 weeks when patients were maintained on stable TPM and concomitant
AED doses. Patients were assessed twice during this phase, every 14 days.
Extension phase: during this phase AED dosing could be changed according to clinical effects.
Monotherapy with TPM also could be tried during this phase. Patients were assessed every month for the first 3
months of this phase (visits 7, 8 and 9). Thereafter, visits occurred every 3 months, unless medically indicated.
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Table 1. Summary of clinical and demographic data.
Patient Gender Date Birth Age at TPM Seizure Age at Etiology/ AEDs at
visit 1 date therapy types seizure onset Imaging TPM onset
1 F 06/07/94 22/10/81 12,9 TC, My, T 3m,4y5m,4y7m Microcephaly CLB/VPA/
CBZ
2 M 06/07/94 31/01/82 12,6 T, TC, My, AA 3m, 3m, 4y, 5y Unknown VPA/NTZ
3 M 06/07/94 29/06/81 13,2 CP, At, My, AA 7y, 8y, 9y, 11y Unknown CBZ/VPA/
PHB
4 F 03/08/94 20/11/84 9,8 T, At, CP 3m, NA, NA Unknown VGB/CBZ/
NTZ
5 M 14/09/94 16/02/80 14,8 TC, AA, My 9y, 9.5y, 11.5y Ventricular VPA/CBZ/
asymmetry ETX
6 F 24/08/94 13/08/90 5,1 TC, At, My, PE 4y, 3y, 3y, 3y Unknown ETX/NTZ
7 F 14/09/94 14/03/86 8,6 IS, CP, T, My 5m, 2y, 3y, 7y Aicardi CBZ/VPA
syndrome
8 M 23/11/94 16/08/82 12,5 TC, C, My, T 8y, 2m, 3.5y, 2m Unknown VGB/CBZ
9 F 08/02/95 18/08/84 10,6 My, T, At, CP 5m, 4y, 4y, 4y Unknown CBZ/CLB
10 M 11/02/94 10/04/85 9,0 At, AA 9m, 9m PI Infarction DPH/CLB
11 M 11/02/94 20/10/85 8,4 At, CP, TC 6m, 6m, 6m Calc.LOR CBZ/PHB
12 M 11/02/94 07/01/90 4,2 At, My, TC 2y, 2y, 1y Aracnoid cyst VPA/CLB
13 F 11/03/94 24/09/81 12,6 AA, TC, At 4y, 4y, 4y Encephalic PHB/DPH
trauma
14 M 15/04/94 24/10/85 8,6 At, T, AA, 4y, 4y, 4y, 4y, 4y, Porencephalic VPA/NTZ
SP, TC cyst
15 M 10/06/94 03/03/90 4,3 My, At, AA 1m, 3m, 3y Unknown VPA/DZP
16 M 24/06/94 01/01/90 4,5 At, My, AA 18m, 18m, 18m, Cerebral VPA/CLZ
atrophy
17 F 12/08/94 26/05/87 7,3 At, T, My, TC 18m, 6y, 4m, 6y Unknown VPA/CLB
18 M 28/10/94 25/11/81 13,1 At, AA NA Cerebral VPA/CLZ
atrophy
19 M 28/11/94 05/07/80 14,6 At, T, TC 11y, 13y, 2y Unknown CBZ/CLZ
Gender: F, female; M, male.
Seizure types: TC, tonic-clonic seizure; My, myoclonic seizure; T, tonic seizure; AA, atypical absence; CP, complex partial
seizure; At, atonic seizure; PE, partial evolving to secondarily generalized seizure; IS, infantile spasm; SP, simple partial seizure.
Age at seizure onset: m, months; y, years; NA, data not available.
Etiology / Imaging: PI, perinatal ischemic; Calc. LOR, calcifications on the left occipital region.
AEDs at TPM onset: AEDs, antiepileptic drugs; TPM, topiramate; CLB, clobazam; VPA, valproate; CBZ, carbamazepine;
NTZ, nitrazepam; PHB, phenobarbital; VGB, vigabatrin; ETX, etosuximide; DPH, phenytoin; DPZ, diazepam; CLZ, clonazepam.
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Starting with visit 1, the follow-up period was 36 months.
TPM was supplied as 25 mg, 50 mg, and 100 mg in bottles of 60 tablets provided by the R.W. Johnson
PRI. The daily dosage was divided in 2 intakes.
Information was obtained through patient diaries about seizure frequency and seizure type. A questionnaire
was used to query parents about patients’ alertness, ability to perform daily activities, interaction with environment
and verbal response. Parents or guardians were asked to inform if patients got better or worse, always comparing
their appreciation with baseline evaluation. The answers were graduated according to the following: 1, very
much improved; 2, much improved; 3, improved; 4, no change; 5, worse; 6, much worse; 7, very much worse.
The measurements of QL were made at visit 1 and at 3, 6, 12, 24 and 36 months.
The safety of study medication was evaluated on the basis of adverse events collected at each
study visit. Physical and neurological examinations, measurement of vital signs and body weight, collection
and counting of unused TPM tablets, laboratory exams (hematology, serum chemistry, urinalysis), reviewed
patient diary and questionnaire assessment were recorded at every visit. ECG recordings were performed
before and at the middle of the treatment.
Subjects were withdrawn from the study for any of the following reasons: subject choice to discontinue the
study, significant protocol violation, severe adverse experience (if hospitalization due to the treatment was required
or if there was a significant interference with the life of the patient), development of intercurrent illness which would put
the subject at increased risk or invalidate the results of the study, worsening of seizures, and lack of efficacy.
RESULTS
Table 2 shows the overall outcome of the patients.
Drop-outs
No patient discontinued treatment during titration phase. Two patients (Cases 18 and 19)
dropped-out during stabilization phase: one (Case 18) because of significant protocol violation –
Table 2. Overall outcome of patients treated with TPM throughout follow-up.
Patient F-up < 3m F-up 3m F-up 6m F-up 12m F-up 18m F-up 24m F-up 36m
1 85 80 68 72 27 39
2 93 96 99 100 100 100
3 85 85 72 59 62 DO5
4 DO 1
5 60 59 65 50 45 20
6 87 90 98 94 95 95
7 59 51 80 90 97 84
8 1 12 15 DO4
9 24 DO3
10 48 30 DO3
11 22 20 54 66 DO5
12 51 56 80 54 DO6
13 70 66 27 DO3
14 51 71 100 100 100 100
15 41 DO3
16 7 77 DO3
17 28 42 44 6 -38 -29
18 DO2
19 DO1
The numbers express the percentage in seizure reduction related to baseline.
F-up, follow-up;1, DO, drop out; , worsening; 2, protocol violation; 3, inefficacy; 4, inefficacy/adverse experience; 5, lost of follow
up; 6, subject choice.
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mother interrupted TPM treatment without our notice – and one (Case 19) due to increased seizure
frequency. Seventeen patients initiated the extension phase but 3 patients (Cases 4, 9 and 15) dropped-
out during the beginning of the extension phase (visits 7, 8 and 9) because worsening of the seizures
(Case 4) and/or inefficacy of the treatment. Fourteen patients were evaluated at month 6, and 7
patients were evaluated at month 36. Reasons for 7 patients discontinue treatment during extension
phase were: lack of efficacy, lost of follow-up, subject choice to try another treatment, and one
patient (Case 8) for inefficacy and adverse experience (powder in the urine, which was interpreted
as possible nephrolithiasis). None of these patients required hospitalization.
Efficacy
Table 3 shows efficacy results. At 36 months, seizure frequency was reduced > 75% in 4, and
< 50% in 3 patients. Two children became seizure free for more than 24 months. Figure 1 shows the
percentage of patients achieving at least 50% of seizure reduction according to seizure type at 6, 12
and 24 months of follow-up. Our patient number 14 is currently in monotherapy with TPM. Patients
who had best outcome achieved significant improvement 3 months after the introduction of TPM
and before other drugs could be changed.
Tolerability
No significant clinical laboratory changes occurred, including other AED levels. No clinically
significant treatment related changes were noted on physical or neurologic examinations or in
electrocardiograms. Figure 2 shows the frequency of the most common side effects that occurred
during the study. Most side effects were CNS related, with the most frequent being somnolence and
anorexia. These were generally transient and tended to disappear with the continuation of the TPM
treatment despite dosage increase (Fig 3).
Table 3. Number of patients who responded to TPM according to the percentage of response.
Seizure frequency reduction Month 3 Month 6 Month 12 Month 18 Month 24 Month 36
> 75% 4 5 5 4 4 4
50-75% 5 5 4 4 1 0
< 50% 7 4 3 1 3 3
Number of patients 16 14 12 9 8 7
Table 4. Quality of life assessment. The numerals express the number of patients throughout the follow-up.
Assessment Alertness Interaction with Daily Verbal
environment activities response
Follow up(month): 3 6 12 24 36 3 6 12 24 36 3 6 12 24 36 3 6 12 24 36
6-Much worse 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0
5-Worse 0 0 0 1 1 0 1 2 0 0 0 0 0 0 0 0 0 0 0 1
4-Unchanged 12 10 8 5 4 9 5 2 1 1 11 7 6 2 2 10 6 5 1 0
3-Improved 1 1 0 0 0 3 3 4 2 2 3 4 3 2 3 4 6 5 6 2
2-Much improved 3 2 4 2 2 4 3 4 4 3 2 2 3 4 2 2 1 2 1 3
1-Very much improved 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 1
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Powder in the urine (1 patient) was the only adverse experience in the long-term phase and
did not require hospitalization.
Quality of life
Table 4 shows the total number of the patients according to the pontuation at 3 (n=16), 6
(n=14), 12 (n=12), 24 (n=8) and 36 (n=7) months of TPM treatment. As far as alertness is concerned
we can verify that at 36 months of treatment, one patient was worse, 4 were unchanged and 2
improved. After 36 months of TPM treatment 5 patients were interacting better with environment, 5
were more active and independent and 6 had their verbal performance improved.
Statistical analysis was not performed due to the small sample size.
DISCUSSION
Our results indicate that TPM may be effective in the treatment of LGS. Four of our patients
(21%) had more than 75% of improvement and 2 of them were seizure free for more than 2 years of
follow-up. They achieved significant improvement soon after TPM was introduced and before other
drug dosages could be changed. Felbamate was approved in the United States for use in LGS based
on the findings of 34% decrease in the frequency of atonic seizures and 19% decrease in the total
frequency of seizures13. In that study, 5 patients (13%) had no seizures during the maintenance
period, which lasted 56 days. Longer periods of follow-up are necessary to evaluate the true efficacy
as some patients who present a favorable response in the beginning of the treatment may fail to
respond to the medication later on. Four of our patients (Cases 1, 5, 16 and 17) have not sustained
the improvement that they achieved at 6 months. On the other hand, the two seizure free patients in
the present study (Cases 2 and 14) achieved the maximum response after 12 months of treatment.
These data reinforce the importance of a long-term follow-up to evaluate drug efficacy.
Lamotrigine (LTG) has been found to be another option in the treatment of patients with
LGS14, 15. Sixteen and 10 LGS patients, respectively, were submitted to treatment with LTG and the
efficacy found in those studies is comparable to our findings. However, LTG discontinuation was
not infrequent due to the occurrence of skin rash, particularly in patients with valproate (VPA)
comedication. This may limit the association of VPA and LTG in some patients. None of our children
Fig 1. This figure shows the percentage of patients achieving at least 50% of seizure reduction according to the
seizure type at 6, 12 and 24 months of follow-up.
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had rash and this side effect seems not to be a problem with TPM, which may suggest that TPM can
be added to VPA without main concern.
As it is shown in Figure 1, best response to TPM at 24 months of treatment was obtained in
tonic seizures, followed by atonic, atypical absence, complex partial, myoclonic and tonic clonic
seizures. Sachdeo et al.16 treated 16 patients with LGS and found better response to TPM in generalized
tonic-clonic seizures. Glauser17 presented the results of 18 LGS patients treated with TPM and
better response occurred in tonic-atonic seizures. Neither our study nor theirs had patients enough to
conclude which type of seizure responds better to TPM.
TPM has a relatively low propensity for clinically significant drug interactions, and its
pharmacokinetic and drug interaction profiles represent a clear advance over the traditional AEDs6, 9. The
half-life of TPM as monotherapy is sufficiently long and consistent to allow once or at most wice-
Fig 2. This figure shows the frequency of the most common side effects that occurred during the study.
Fig 3. Somnolence and anorexia, the most frequent side effects, tended to disappear with the continuation of the
TPM treatment despite dosage increase.
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daily dosing. Renal excretion is the major route of elimination of TPM9. revious observations indicate
no significant changes in plasma levels of traditional AEDs when TPM is added6. Our results support
these findings, as there were no major changes in plasma levels of other AEDs in this study.
Most adverse events observed during TPM add-on therapy are CNS related18-22. In a review
of 1,809 individuals treated with TPM, Shorvon22 found dizziness and fatigue as the most common
side effects. Our cognitively impaired children could not complain of dizziness or fatigue. We found
somnolence and anorexia as the most frequent adverse events in our patients. Some of them presented
anorexia but no weight loss, which could be of concern in children. Weight loss with TPM is
infrequently a limiting factor during treatment and tends to plateau during long-term therapy22. As is
shown in Figure 3, somnolence and anorexia tended to subside as the study continued despite the
increasing of TPM dosage.
There is a small but definite increased risk for nephrolithiasis with TPM, which was observed in
1.5% of the patients22. None of the stones required open surgery, and three-fourths were passed
spontaneously. One of our patients possibly has had nephrolithiasis and we interrupted TPM treatment.
His follow-up showed spontaneous resolution of this effect. The absence to date of any clinically important
changes in laboratory parameters of tests of neurologic or special sense function is most encouraging.
According to our QL questionnaires approximately one third of our patients had their QL
improved after TPM treatment. We considered this finding an important one due to the poor QL
profile of LGS patients.
It has been important to find new options in the treatment for such a devastating epileptic
condition in order to alleviate the symptoms and improve the QL of those patients. It is for such
patients that new AEDs are required23.
We still can not give the final word about TPM in LGS because of the small number of
patients but we found encouraging results which suggest we should continue pursuing this treatment.
We conclude that TPM may be useful as adjunctive therapy in the treatment of LGS. We
found that the efficacy of TPM was maintained in long-term treatment in more than 40% of patients
and that long-term safety was confirmed. Most adverse events were CNS related and tended to
subside as the treatment continued. Our results should be reinforced by controlled studies with a
larger number of patients.
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